产品详细信息

Description: The 13A4 monoclonal antibody recognizes mouse Prominin-1 (sometimes also referred to as CD133 and, in the case of the human orthologue, as AC133), a 115-120 kDa pentaspan transmembrane (5-TM) domain glycoprotein. Prominin-1 is expressed on primitive cells such as hematopoietic stem and progenitor cells, neural and endothelial stem cells, retina and retinoblastoma, as well as developing epithelium. To date, the function and ligand of Prominin-1 are unknown. The 13A4 antibody does not cross react with rat, human, chicken, or Drosophila antigen but has been reported to work in canine/dog.

Applications Reported: This 13A4 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This 13A4 antibody has been tested by flow cytometric analysis of mouse bone marrow cells. This may be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome.

When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information.

Excitation: 405 nm; Emission: 436 nm; Laser: Violet Laser

Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company.

靶标信息

The CD133 (AC133) antigen is a 97 kDa glycoprotein, with 5 transmembrane domains, that shows up as a 120 kDa band on protein gels due to glycosylation. CD133 is a cell surface marker expressed by immature hematopoietic stem cells but not mature blood cells. In addition to hematopoietic stem and progenitor cells, CD133 has been found to be a marker for other stem and progenitor cells including neural and embryonic stem cells. CD133 has been shown to be expressed in cancers, including some leukemias and brain tumors, that may be derived from stem cells. Low level expression could also be detected in the kidney, pancreas, placenta, and fetal liver. Mutations in this gene have been shown to result in retinitis pigmentosa and Stargardt disease. Expression of the CD133 gene is also associated with several types of cancer. CD133 is expressed from at least five alternative promoters that are expressed in a tissue-dependent manner, and multiple transcript variants encoding different isoforms have been found.